COVID-19 vaccine weekly safety report - 17-03-2022

To 13 March 2022, the total number of adverse event reports received where the brand of the COVID-19 vaccine was not specified was 526.

Reported side effects for COVID-19 vaccines

The most frequently reported side effects suspected to be associated with the vaccines include headache, muscle and joint pain, fever, chills and nausea. Skin reactions at the site of the injection are also common and can include pain, swelling, redness and an itchy rash. These are recognised side effects of vaccination and are usually transient and mild. More information about what to expect and how to manage any symptoms after you receive your vaccine are available from NPS MedicineWise.

Vaccine safety in children and adolescents

The TGA is closely monitoring adverse event reports in people aged under 18 years. To 13 March 2022, we have received about 3,800 reports from approximately 3.5 million doses of Comirnaty (Pfizer) and Spikevax (Moderna) in 12-17 year olds. The most commonly reported reactions are chest pain, headache, dizziness, nausea and fever.

The TGA is also closely monitoring adverse event reports in 5-11 year olds. To 13 March 2022, we have received 886 reports from approximately 1.4 million Comirnaty (Pfizer) doses administered in this age group. The most common reactions reported included chest pain, vomiting, fever, headache and nausea. We have received 17 reports of suspected myocarditis and/or pericarditis in this age group. Following review of information in the reports, none were likely to represent myocarditis. Two reports in 10-year-old boys possibly represent mild pericarditis when assessed against internationally accepted criteria for this condition.

Evidence from clinical trials and real-world experience from overseas indicate that side effects most commonly seen in this age group were mild and temporary similar to the safety profile in older populations. In clinical trials of over 2000 children, most side effects were reported in the first 2-3 days after vaccination with the most common being a sore arm (70% of children), headache (25%) and tiredness (25%).

In the US, over 8 million doses of the vaccine have already been given to children aged 5–11 from 3 November to 19 December 2021. A review of active and passive vaccine surveillance data published by the US Centers for Disease Control and Prevention (CDC) found similar safety findings to the clinical trial with most side effects being mild. A survey conducted shortly after vaccination found that about 5% of children missed school (usually only a single day or less) after a first dose and 7% missed school after a second dose.

Reports of more serious effects following vaccination in children in the US were extremely rare with 100 reports from 8.7 million vaccine doses - the most common were fever, vomiting and in some cases seizures. Importantly, reports of myocarditis were also very rare in the US, with 11 confirmed reports from over 8 million doses - these were all mild cases.

New safety data from the AusVaxSafety survey indicates that the Comirnaty (Pfizer) vaccine is well tolerated in children aged 5-11 years, with fewer adverse reactions reported after vaccination than in older Australians. The most frequently reported side effects include local reactions at the injection site such as pain, swelling, redness and itching. Headache and fatigue were also common.

More information and frequently asked questions about COVID-19 vaccines in children are available on the National Centre for Immunisation Research and Surveillance website

Booster doses

The TGA is monitoring the safety of booster vaccine doses in adults. It is not expected that the types of side effects will be different to first and second vaccine doses based on the results of clinical trials, and observations from regulators overseas where more booster doses have been given. Together with other international regulators we are monitoring the type and frequency of adverse events after different vaccine combinations.

To 13 March 2022, approximately 12.2 million boosters or third doses have been administered in Australia. We have received approximately 5,500 reports of suspected adverse events identified as a third or booster dose. These reports do not suggest any emerging safety concerns with use of a booster dose that is different to the first and second vaccine doses received.

Our booster or third dose reports include a small number of cases of myocarditis and pericarditis (inflammation of the heart). This is a recognised risk with the Comirnaty (Pfizer) and Spikevax (Moderna) vaccines and we are closely monitoring these events. So far, reports after booster doses are very rare with myocarditis reported in less than 1 in every 100,000 people after they receive a booster dose. A US study of active and passive surveillance data of COVID-19 vaccine booster doses (September 2021–February 2022) found a similar trend. In men aged 18-24 years, the reporting rate of likely myocarditis was less than 1 in 100,000 mRNA vaccine booster doses compared to about 6 in 100,000 second doses. There is no indication that these events are more serious than after earlier doses. A similar US study of COVID-19 vaccine booster doses in adolescents (December 2021 - February 2022) found the reporting rate of likely myocarditis was about 1 in 100,000 Comirnaty (Pfizer) booster doses in adolescent boys who had received the Comirnaty (Pfizer) vaccine for their first and second doses. This reporting rate is lower than was observed after a second dose.

The most common adverse events reported to the TGA following a booster dose are swollen lymph nodes (also called lymphadenopathy), headache, fatigue, chest pain and muscle pain. Swollen lymph nodes are a normal and known side effect of vaccines and occur when the immune system is stimulated and were seen in the clinical trials. More detail about this potential side effect is given in a previous vaccine safety report on the 6 January 2022.

What we know about the safety of different vaccine combinations

Based on data from the Australian Immunisation Register, we can see that most people under the age of 50 years received 3 mRNA vaccines – this was most commonly 3 doses of Comirnaty (Pfizer). For people in the 50-59 age group, there was more of a mixed picture with over half of them receiving 3 doses of an mRNA vaccine and the rest getting an mRNA vaccine booster after receiving initial doses of Vaxzevria (AstraZeneca). In the over 60 age group, most people received an mRNA vaccine booster after getting Vaxzevria (AstraZeneca) for their first 2 doses.

For the adverse event reports received by the TGA following a booster dose, many do not give details about which COVID-19 vaccines the person received for their first and second doses. Taking into account the limitations in this reporting data, we have not observed any patterns of adverse events which suggests different vaccine combinations are more likely to lead to serious adverse events.

The US surveillance study of booster doses found that in people who had received 3 mRNA doses, adverse reactions were reported less frequently after the booster dose than after the second dose.

To improve our vaccine safety monitoring, we encourage people reporting adverse events to tell us as much information as possible about their experience, including the type of COVID vaccines they have received, and which dose the adverse event relates to.

More information about how to report a suspected side effect to a COVID-19 vaccine is available on the TGA website.

Reports of death in people who have been vaccinated

Large scale vaccination means that some people will experience a new illness or die within a few days or weeks of vaccination. These events are often coincidental, rather than being caused by the vaccine. As the number of people being vaccinated has increased, so has reporting of fatal events with a temporal association with vaccination. Review of these individual reports and patterns of reporting does not suggest that the vaccines played a role in the vast majority of these deaths.

The TGA closely reviews all adverse events after COVID-19 vaccination where a fatal outcome is reported. Read more about this process in a previous report. Since the beginning of the vaccine rollout to 13 March 2022, about 55.1 million doses of COVID-19 vaccines have been given. The TGA has identified 11 reports where the cause of death was linked to vaccination from 798 reports received and reviewed. The deaths linked to vaccination occurred after the first dose of Vaxzevria (AstraZeneca) - 8 were thrombosis with thrombocytopenia syndrome (TTS) cases, 2 were linked to Guillain-Barre syndrome (GBS) and one was a case of immune thrombocytopenia (ITP).

The 11 deaths likely to be related to vaccination occurred in people aged 34–81 years old. There have been no deaths in children, adolescents or younger adults determined to be linked to COVID-19 vaccination.

AusVaxSafety - a national survey on COVID-19 vaccine safety

AusVaxSafety has collected responses from over 6 million Australians about adverse events after they have received a COVID-19 vaccine. It tells us what proportion of people experience an adverse event and what the most common reactions are. It also measures how frequently people go to the doctor or miss work or study because of an adverse event. Reassuringly, survey results largely reflect what was seen in the clinical trials, with injection-site reactions, fatigue, headache, and muscle and joint pain being the most common reactions.

On the AusVaxSafety website, survey results are presented for each COVID-19 vaccine:

• Comirnaty (Pfizer) adult formulation and paediatric formulation (5-11 years)
• Spikevax (Moderna)
• Vaxzevria (AstraZeneca)
• Nuvaxovid (Novavax)

For each vaccine, survey results are given for different age groups and different populations, such as Aboriginal and Torres Strait Islander people, those affected by cancer or who have received a transplant, and pregnant women.

Comirnaty (Pfizer) mRNA vaccine

To 13 March 2022, about 37.4 million doses of Comirnaty (Pfizer) have been administered in Australia.

The TGA is actively investigating reports of myocarditis (inflammation of the heart) and/or pericarditis (inflammation of the membrane around the heart) associated with mRNA vaccines. We continue to work with international regulators on this safety signal (see below).

Up-to-date information for Comirnaty (Pfizer), including details of potential side effects , can be found in the Consumer Medicine Information (for consumers) and Product Information (for health professionals).

Spikevax (Moderna) mRNA vaccine

The Spikevax (Moderna) vaccine can now be given to 6–11 year olds in Australia. This follows provisional approval by the TGA and a recommendation by the Australian Technical Advisory Group on Immunisation (ATAGI). There is not a separate paediatric formulation of the Spikevax (Moderna) vaccine. However, for the 6-11 year age group, the dose is half that used for the primary vaccine course in older children and adults. The Comirnaty (Pfizer) children's formulation continues to be the only COVID-19 vaccine approved for children who are 5 years of age. No COVID-19 vaccines are currently approved for children 4 years of age and under.

The TGA is closely monitoring the safety of this vaccine in children and adults. To 13 March 2022, about 3.9 million doses of Spikevax (Moderna) have been administered in Australia.

The TGA is actively investigating reports of myocarditis (inflammation of the heart muscle) and/or pericarditis (inflammation of the membrane around the heart) associated with mRNA vaccines. We continue to work with international regulators on this safety signal (see below).

Up-to-date information for Spikevax (Moderna), including details of potential side effects, can be found in the Consumer Medicine Information (for consumers) and Product Information (for health professionals).

Nuvaxovid (Novavax) vaccine

The Nuvaxovid (Novavax) vaccine has been provisionally approved for adults in Australia after meeting the TGA's high standards for quality, safety and effectiveness.

To 13 March 2022, about 46,900 doses of Nuvaxovid (Novavax) have been administered in Australia. The TGA has received 142 reports of suspected adverse events. We are closely monitoring these reports which are beginning to appear in the TGA’s publicly accessible Database of Adverse Event Notifications. The most commonly reported reactions include headache, paraesthesia, chest pain, fatigue and dizziness. To date, no safety signals have been identified for Nuvaxovid (Novavax) based on this limited number of reports.

Paraesthesia is an unusual feeling in the skin, such as tingling or a crawling sensation, and has also been reported for other COVID-19 vaccines. It is not known why paraesthesia sometimes occurs after vaccination, but it is thought it may be a stress-related response to immunisation rather than an immune reaction.

In the AusVaxSafety survey(link is external), the most commonly reported reactions to Nuvaxovid (Novavax) are fatigue, injection-site reactions and headache. These are expected side effects which were also seen in clinical trials.

More information for Nuvaxovid (Novavax), including details about its ingredients and potential side effects, can be found in the Consumer Medicine Information (for consumers) and Product Information (for health professionals).

Vaxzevria (AstraZeneca) vaccine

To 13 March 2022, about 13.8 million doses of Vaxzevria (AstraZeneca) have been administered in Australia. However, very few doses are now being used, particularly since the end of 2021. This vaccine has recently received provisional approval to be used as a booster dose. Individuals seeking a booster dose of Vaxzevria (AstraZeneca) should discuss this with their health professional.

The TGA is closely monitoring rare reports of blood clots with low blood platelets (also called thrombosis with thrombocytopenia syndrome or TTS) linked to this vaccine, immune thrombocytopenia (ITP) and Guillain-Barre Syndrome (GBS). These are rare but serious side effects, with TTS reported in about 2 in every 100,000 people after receiving Vaxzevria (AstraZeneca) and ITP and GBS reported in about one in every 100,000 people. Detailed information of our analysis of these adverse effects is available in a previous vaccine safety report.

With only limited use of the Vaxzevria (AstraZeneca) vaccine now in Australia, we have not received any new reports confirmed or probable TTS this year. The total number of TTS cases reported in Australia is 172. Of these, 148 (83 confirmed, 65 probable) were related to a first dose of Vaxzevria (AstraZeneca) and 24 to a second dose (5 confirmed, 19 probable).

To 13 March 2022, we have received a total of 160 reports of suspected GBS – 9 of these were reported to us this year but 6 of them had a vaccination date in 2021. Similarly, we have received 87 reports of suspected ITP – 2 of these were reported this year but had a vaccination date in 2021. There has been no change in the reporting rate of ITP, GBS or TTS this year. The total number of reports can fluctuate slightly over time as duplicate reports are identified or cases reclassified when we receive additional information.

Updates to the Product Information

The PI for Vaxzevria (AstraZeneca) has been updated to include the potential adverse events paraesthesia and hypoaesthesia (altered sensation of the skin), and a rare neurological condition called transverse myelitis. These events were not observed in the clinical trials but have been identified during post-market surveillance. Updates have also been made to the prescribing information for ITP.

Paraesthesia and hypoaesthesia

The potential adverse events paraesthesia and hypoaesthesia have been added to the PI under section 4.8 Adverse effects. Paraesthesia is an unusual feeling in the skin, such as tingling or a crawling sensation, and hypoaesthesia is a decreased feeling or numbness. These adverse events have also been reported for other COVID-19 vaccines. It is not known why they sometimes occur after vaccination, but it is thought they may be a stress-related response to immunisation rather than an immune reaction. Our analysis indicates these symptoms are usually mild. However, if they persist, people should seek medical attention.

Transverse myelitis

A warning about transverse myelitis has been included in the PI under sections 4.4 Special warnings and precautions for use and 4.8. This follows a review by the European Medicines Agency’s Pharmacovigilance Risk Assessment Committee which concluded there is a reasonable possibility of a causal link to the vaccine.

Transverse myelitis is a neurological disorder of the spinal cord caused by inflammation and has been reported very rarely following vaccination. It has multiple causes including infection, in particular viral infection, and underlying demyelinating disease such as multiple sclerosis. However, transverse myelitis can present with no known cause and this occurs at a background rate of 1-4 people per million in the general population.

Transverse myelitis develops quickly over hours to days and worsens over weeks. Symptoms include burning, tingling or numbness that starts in the feet, muscle weakness in the arms and legs and, in some cases, problems with bladder or bowel control. These effects can be long-lasting. Health professionals should be alert to the signs and symptoms to ensure early diagnosis, supportive care and appropriate treatment, and to rule out other causes.

To 13 March 2022, the TGA has received 19 reports of suspected transverse myelitis following Vaxzevria (AstraZeneca). We are currently monitoring these reports and will provide more information if it arises.

Immune thrombocytopenia

Amendments to the wording about thrombocytopenia have also been made to the PI under Coagulation disorders in section 4.4. This includes the following warning "If an individual has a history of a thrombocytopenic disorder, such as ITP, the risk of developing low platelet levels should be considered before administering the vaccine and platelet monitoring is recommended after vaccination."

More general information for Vaxzevria (AstraZeneca), including details of potential side effects can be found in the Consumer Medicine Information (for consumers) and Product Information (for health professionals).

Myocarditis and pericarditis with mRNA vaccines

ATAGI continues to emphasise that the protective benefits of the mRNA vaccines far outweigh the rare risk of these side effects in all eligible age groups.

ATAGI advises that people who develop myocarditis attributed to their first vaccine dose should defer further doses of an mRNA COVID-19 vaccine and discuss this with their treating doctor.

For those with suspected pericarditis after a first dose, future dose recommendations depend on test results and the person’s age and sex. Refer to expert Guidance on myocarditis and pericarditis after mRNA COVID-19 vaccines for more information.

What are myocarditis and pericarditis?

Myocarditis is inflammation of the heart, and pericarditis is inflammation of the membrane around the heart. They can occur as rare adverse events after vaccination with the mRNA vaccines Comirnaty (Pfizer) and Spikevax (Moderna).

When do myocarditis and pericarditis occur?

Cases typically occur within 10 days, with symptom onset often within 5 days of vaccination. Some published evidence found pericarditis symptoms may occur later, commonly 2-3 weeks after vaccination. Our analysis indicates that most of the patients with likely myocarditis experienced symptoms within 3 days of vaccination.

Do myocarditis and pericarditis occur after a booster dose?

Myocarditis and pericarditis can occur after a booster dose but this is rare. The rate of reporting of myocarditis and pericarditis is less than 1 in every 100,000 people after a booster dose. There is no indication that these events are more serious than after earlier doses.

To 13 March 2022, from approximately 12.2 million booster or third doses, we have received 12 reports of likely myocarditis and 47 reports of likely pericarditis for Comirnaty (Pfizer) and 10 reports of likely myocarditis and 13 reports of likely pericarditis for Spikevax (Moderna). The median age of affected individuals was 33 years old.

Myocarditis following COVID-19 vaccination is most likely to be reported in adolescents and young men, whereas the median age of people who have received a third or booster dose of a COVID-19 vaccine to date is 53 years. The TGA will continue to closely monitor myocarditis and pericarditis following booster or third doses as the booster roll-out extends to younger age groups.

We are also closely monitoring myocarditis and pericarditis with different vaccine combinations for first and second doses and boosters. At this point, although we have only a small number of reports of pericarditis and/or myocarditis, we have not seen any patterns or trends in the data to indicate any difference with mixed vaccine combinations.

Who is at risk of these heart problems?

Myocarditis is more commonly reported after the second dose in 12-17 year-old boys (11 cases per 100,000 Comirnaty doses and 16 cases per 100,000 Spikevax doses) and men under 30 (7 cases per 100,000 Comirnaty doses and 16 cases per 100,000 Spikevax doses). However, even in this population it remains rare. A similar trend for myocarditis has also been observed in a descriptive study of reporting data in the US.

A European review of myocarditis and pericarditis data in teenage boys and young men (12-29 years old) found for Comirnaty, there were 2–6 extra cases of myocarditis per 100,000 vaccinated individuals after a second dose compared to unvaccinated individuals. For Spikevax, there were 13–19 extra cases of myocarditis per 100,000 vaccinated individuals compared to unvaccinated individuals. A study by the Centers for Disease Control and Prevention (CDC) (pdf,606kb) in the US found in 18–39 years olds there was approximately 2 extra cases of myocarditis and pericarditis reported per 100,000 Comirnaty (Pfizer) second doses and 3 extra cases per 100,000 Spikevax (Moderna) second doses.

How serious are myocarditis and pericarditis?

Myocarditis is often mild, and cases usually resolve after a few days with treatment and rest. Some cases are more serious and need to be treated in hospital. Our analysis has found about half of the patients with suspected myocarditis were admitted to hospital. Nine people with likely myocarditis or pericarditis were treated in intensive care. This represents less than 1% of all likely cases. Most patients admitted to hospital were discharged within 4 days.

In the US descriptive study of myocarditis cases, the majority of those under 30 years of age were admitted to hospital but symptoms had resolved by the time they were discharged. The most common treatment for these individuals was nonsteroidal anti-inflammatory drugs, such as ibuprofen.

Evidence from a US surveillance survey (pdf,1.1Mb) of patients who had myocarditis following vaccination indicates that most patients fully recover without lasting impacts on their quality of life or ability to work. The survey, which was conducted 3 months after the initial myocarditis diagnosis, involved mostly men under 30 years after their second vaccine dose. There were no deaths from myocarditis reported in these patients.

What myocarditis and pericarditis symptoms should I look out for?

We encourage people to seek medical attention if they experience symptoms that could suggest myocarditis or pericarditis. This includes chest pain, palpitations (irregular heartbeat), fainting or shortness of breath, particularly if they occur within 1-5 days of vaccination.

Initial tests for those presenting with symptoms include ECG, troponin levels and chest X-ray. Brief guidance on the initial assessment of children and adolescents with symptoms has been published by the Paediatric Research in Emergency Departments International Collaborative (PREDICT) network.

What does the TGA know about Australian myocarditis and pericarditis cases?

Reports received by the TGA of suspected myocarditis and pericarditis for the 2 mRNA vaccines are provided in Table 1. We have reviewed these reports against an internationally accepted criteria to classify the likelihood of myocarditis. This assessment does not determine whether cases have been caused by vaccination. Tables 2 and 3 present the rates of myocarditis and pericarditis.

We have received a small number of reports of myocarditis and pericarditis after a third or booster dose. These reports are very rare and there is no indication that they are more serious than after earlier doses.

Table 1. Reports of suspected myocarditis and pericarditis received by the TGA to 13 March 2022 ¥

		Comirnaty (Pfizer) (37.4 million doses given)		Spikevax (Moderna) (3.9 million doses given)
		All cases	Cases in adolescents (12-17 years)	All cases	Cases in adolescents (12-17 years)
Suspected myocarditis cases*		1,159	193	153	27
Likely myocarditis†‡	Level 1	35	7	1	0
	Level 2	329	107	51	15
	Level 3	93	12	13	3
Unlikely myocarditis		302	25	35	3
Insufficient information		400	42	53	6
Suspected pericarditis cases		2,467	166	248	12
Likely pericarditis£		953	65	80	3

* Cases reporting both myocarditis and pericarditis are included in suspected myocarditis cases.

¥The total number of reports can fluctuate slightly over time as duplicate reports may be identified and deleted and cases may be reclassified after receiving additional information.

‡ Cases classified as level 1 are confirmed to be myocarditis based on strong clinical evidence including the patient's symptoms, and results of tests and imaging indicating a diagnosis of myocarditis. Level 2 cases are probably myocarditis based on a combination of symptoms and routine tests for heart conditions. Level 3 cases are possibly myocarditis based on symptoms and a doctor's report that myocarditis is the most likely diagnosis in the absence of medical tests and investigations. For all cases of suspected myocarditis, where possible, other known causes of the patient's symptoms or test results are ruled out before cases are classified.

† The youngest case classified as 'likely myocarditis' to date was 12 years old.

£ Classification of likely pericarditis is based on the patient's symptoms and test results and the absence of other known causes of pericarditis.

Rates of myocarditis by age, sex and dose are given for Comirnaty (Pfizer) and Spikevax (Moderna) in Table 2. The estimated reporting rates in Australia appear similar to overseas rates. The rates for Spikevax (Moderna) are less certain due to low numbers of cases overall. Rates of pericarditis by age are given for Comirnaty (Pfizer) and Spikevax (Moderna) in Table 3.

Table 2. Rates of likely myocarditis cases following the mRNA vaccines‡ A. Comirnaty (Pfizer)

Age (years)	All doses		Second doses
	Rate* per 100,000 doses		Rate* per 100,000 doses
	Male	Female	Male	Female
12-17	6.5	1.3	10.6	2.3
18-29	3.9	1.1	6.9	1.9
30-39	1.4	0.6	1.9	0.6
40-49	0.6	0.5	1.1	0.9
50-59	0.4	0.3	0.1	0.3
60-69	0.1	0.2	0	0
70+	0	0.1	0	0.4
All ages*	1.9	0.6	3.6	1.1

B. Spikevax (Moderna)

Age (years)	All doses		Second doses
	Rate* per 100,000 doses		Rate* per 100,000 doses
	Male	Female	Male	Female
12-17	8.6	1.8	15.8	2.6
18-29	7.4	0.9	16.0	1.2
30-39	2.5	0.3	5.1	0.0
40-49	1.1	0.3	1.7	0
50-59	0.3	1.0	0	2.5
60-69	0	0.3	0	0
70+	0	0.2	0	0
All ages*	2.7	0.7	8.2	1.1

* The rate includes cases of myocarditis that occurred after vaccination but may not be vaccine related.

‡ To 13 March 2022, from about 1.4 million vaccine doses given, no likely cases of myocarditis have been reported in children aged 5-11 years.

Table 3. Rates of likely pericarditis cases following the mRNA vaccines‡

Age (years)	Rate* per 100,000 doses
	Comirnaty (Pfizer)	Spikevax (Moderna)
12-17	2.0	0.9
18-29	3.3	4.4
30-39	3.8	4.1
40-49	2.3	1.7
50-59	1.3	0.6
60-69	0.7	0.2
70+	0.2	0
All ages*	2.3	2.1

* The rate includes cases of pericarditis that occurred after vaccination but may not be vaccine related.

‡ To 13 March 2022, from about 1.4 million vaccine doses given, two possible cases of mild pericarditis have been reported in children aged 5-11 years. As this number is so low, we are unable to estimate reliable rates of pericarditis in this age group.

We continue to monitor Australian reports on myocarditis and pericarditis and will provide regular updates in this report as more information becomes available. We are also working closely with international medicines regulators to share emerging safety information.

For more information, see guidance on myocarditis and pericarditis developed by ATAGI and the Cardiac Society of Australia and New Zealand (CSANZ).

Useful links

Tested positive for COVID-19? Find out what you need to do

Watch this video to find out how the TGA monitors and reports the safety of COVID-19 vaccines(

ATAGI update following weekly COVID-19 meeting - 9 March 2022

The latest vaccine recommendations from ATAGI

Myocarditis and pericarditis following COVID-19 mRNA vaccines – Melbourne Vaccine Education Centre – 10 March 2022

COVID-19 vaccines: Frequently asked questions – 15 March 2022

COVID vaccines - is it true? - 17 February 2022

RMIT ABC Fact Check

Latest advice on COVID-19 vaccination for pregnant and breastfeeding women - 18 August 2021

Coronavirus (COVID-19) case numbers and statistics

Australia's COVID-19 vaccine rollout

TGA COVID-19 vaccines hub

Australian Government Department of Health COVID-19 vaccines hub

COVID vaccine information in your language

Database of Adverse Event Notifications (DAEN)

Nuvaxovid (Novavax) vaccine – clinical trials

Comirnaty (Pfizer) vaccine - phase III clinical trial

Comirnaty (Pfizer) vaccine - clinical trials in children under 12 years

Vaxzevria (AstraZeneca) vaccine - phase III clinical trial

Spikevax (Moderna) vaccine - phase III clinical trial